Abstract: Anti-platelet aggregation, coagulation and lipid regulation are the important measures of clinicaltreatment and prevention of ischemic stroke(IS). Clopidogrel, warfarin and statins are the commonlyused therapy. However, genetic factors that lead to drug metabolizing enzymes, transporters andtargets of drug response associated protein for activity individual differences, thus affecting theclinical drug efficacy and toxicity. In this review, we discuss the pharmacogenetics of clopidogrel,warfarin and statins of IS therapy, and analyze the gene polymorphism which affecting the drugefficacy and toxicity to facilitate the individualized treatment and prevention of IS.

Key words: Brain infarction; Pharmacogenetics; Polymorphism; genetic; Clopidogrel; Warfarin; Statins

摘要： 抗血小板聚集、抗凝及血脂调控药物是临床治疗与预防缺血性卒中（ischaemic stroke，IS）的重要措施，而氯吡格雷、华法林及他汀类药物是其中常用的治疗药物；然而，遗传因素可导致药物代谢酶、转运体及作用靶点等药物反应相关蛋白活性出现个体差异，从而影响药物的疗效和毒副作用。本文将探讨氯吡格雷、华法林及他汀类药物治疗IS的遗传药理学，并分析影响药物疗效及毒副作用的基因多态性，以利个体化的IS治疗与预防

关键词: 脑梗死; 遗传药理学; 多态现象; 遗传; 氯吡格雷; 华法林; 他汀类药物